Clinical trial · Observational
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- Up to 12 months
- description
- Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
Secondary outcomes (8)
- measure
- Drugs administration dosage description
- timeFrame
- Up to 12 months
- description
- Description of the different monthly drug administration regimens
- measure
- Objective response rate and control rate
- timeFrame
- Up to 12 months
- description
- Objective response rate and control rate according to RECIST 1.1 criteria in the general population
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years old; * Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC; * Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification; * Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not; * Alive patients not opposed to the use of their data Exclusion Criteria: * Patient under guardianship or curatorship at the date of the study ; * Patients alive at the time of the study who are opposed to the use of their data * Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
References
Publications (0)
Data not yet available